Osteoporosis in inflammatory bowel disease

Gut

Volumn 52, Issue 1, 2003, Pages 63-64

  Compston, J ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; STRONTIUM RANELATE; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D;

BONE DENSITY; BONE MINERAL; CALCIUM INTAKE; CROHN DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; ENTERITIS; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INFUSION; INTESTINE ABSORPTION; MORBIDITY; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY; SLOW RELEASE FORMULATION; VITAMIN SUPPLEMENTATION;

ADULT; BONE DENSITY; DIPHOSPHONATES; FEMALE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 0037215453     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.1.63     Document Type: Short Survey

References (10)

1. Vestergaard P, Krogh K, Rejnmark L, et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000;46:176-81.
2. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000;133:795-9.
3. Compston JE. Pharmacological interventions for postmenopausal osteoporosis: An evidence-based approach. Rheumatology 2000;39:1309-15.
4. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fracture and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
5. Meunier PJ, Roux C, Ortolani S, et al. Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos Int 2002;13(suppl 1): O45.
6. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
7. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;39:292-9.
8. Wallach S, Sohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
9. Hanauer SB. New steroids for IBD: Progress report. Gut 2002;51:182-3.
10. Haderslev KV, Tjellesen L, Sorensen HA, et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-46.